[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"musculoskeletal-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:musculoskeletal-injury":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,42,70,104,125,163,182,213,240,269,295,320,343],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100515263","emotional-awareness-and-expression-therapy-for-people-with-persistent-pain-following-orthopedic-trauma-100515263",false,"NCT05989230","Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma","Emotional Awareness and Expression Therapy for People With Persistent Pain Following Orthopedic Trauma: A Pilot Feasibility Study","Inclusion Criteria:\n\n* One or more acute orthopedic injuries\n* The patient sustained an orthopedic injury including, but not limited to:\n\n  * Pelvic or acetabulum fracture\n  * Open\u002Fdisplaced comminuted fracture of long bones\n  * Upper extremity injuries with a major nerve involvement\n  * Injuries with significant injuries to major blood vessels\n  * Traumatic amputation of big toe, thumb, or proximal to the wrist or ankle.\n* Initial admission to the trauma or orthopedic center\u002Fservice of the participating hospital OR all necessary screening and patient characteristic data available in medical record (determination based on information available at time of enrollment)\n* 18 years old or older\n* Received operative fixation for at least one acute orthopaedic injury at a participating hospital. Patients should be recruited at the time of primary injury, not revision or complication surgery\n* Average Brief Pain Inventory Score \\> 3\u002F10\n* Presence of pain most days (\\> 3 days\u002Fweek) for past three months\n\nExclusion Criteria:\n\n* peri-prosthetic fractures of the femur (regardless of etiology)\n* non-ambulatory due to an associated spinal cord injury\n* non-ambulatory pre-injury\n* currently pregnant\n* moderate or severe traumatic brain injury (TBI), as evidenced by intracranial hemorrhage present on admission CT\n* major amputation(s) of the upper or lower extremities\n* non-English speaking\n* Likely to have severe problems with maintaining follow-up for any of the following reasons:\n\n  * The patient has been diagnosed with a severe psychiatric conditions\n  * The patient has current alcohol and\u002For drug addiction based on medical record or patient self-report.\n  * The patient is intellectually challenged without adequate family support\n  * The patient lives outside the hospital's catchment area\n  * The patient follow-up is planned at another medical center\n  * The patient is a prisoner\n  * The patient is homeless\n  * Other","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this single-arm trial is to determine the feasibility of emotional awareness and expression therapy (EAET) for individuals with persistent pain following orthopedic trauma. As part of this study, participants will be asked to attend weekly EAET treatment sessions and complete assessments (including pre-treatment, post-treatment, and follow-up) consisting of questionnaires and sensory testing procedures.",[26,27,28],"Orthopaedic Trauma","Chronic Pain","Musculoskeletal Injury","RECRUITING","2026-06-17",{"date":32,"type":33},"2026-06-18","ACTUAL",{"date":35,"type":33},"2024-08-28",{"date":37,"type":20},"2027-09-01",{"name":39,"class":40},"Johns Hopkins University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100564937","baseline-acl-injury-risk-screening-and-normative-data-100564937","NCT06635668","Baseline ACL Injury Risk Screening and Normative Data","Inclusion Criteria:\n\n* Healthy athletes participating in formal, organized, competitive sports between the ages of 10 and 65 years old",true,"10 Years","65 Years",{"count":52,"type":20},5000,"OBSERVATIONAL","This is a prospective, observational cohort study aimed at establishing a database of normative biomechanics for healthy athletes and surveying these athletes for 12 months following baseline testing for the occurrence of new musculoskeletal injuries, with a particular emphasis on ACL injuries.",[56,57,28],"ACL Injury","Anterior Cruciate Ligament Injuries",[59,60],"Athletes","Biomechanics","2026-04-14",{"date":63,"type":33},"2026-04-17",{"date":65,"type":33},"2022-07-19",{"date":67,"type":20},"2033-07-01",{"name":69,"class":40},"Sanford Health",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":17,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100604140","phase-3-topical-diclofenac-vsoral-ibuprofen-for-msk-pain-in-children-100604140","NCT07145645","Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children","Topical Diclofenac vs. Oral Ibuprofen for Musculoskeletal Pain in Children: A Multi-centre, Randomized Pilot Feasibility Trial","TOP-MAP","Inclusion Criteria:\n\n1. Age 6 to 18 years old.\n2. Injury less than or equal to 4 days old\n3. Non-fractured MSK soft-tissue injury (ankle or knee, confirmed clinically and\u002For radiographically)\n4. Pain score of more than or equal to 3 on the verbal numerical rating scale, with movement in the past 2 hours or before analgesia\n5. Willing and able to complete follow-up surveys as per study protocol\n\nExclusion Criteria:\n\n1. Previous enrolment in the trial\n2. Barriers to topical treatment application, including skin conditions (e.g. eczema, infection, open wounds) or overlying material (e.g., rigid cast) which would make applying topical treatment impossible.\n3. Any other history, condition, therapy, or uncontrolled intercurrent illness, which could, in the opinion of the Qualified Medical Investigator or treating physician, would make the participant unsuitable for this study\n4. Any contraindication to NSAID use including but not limited to a history of GI bleeding, gastric ulcer, inflammatory bowel disease, prior cerebrovascular bleeding, bleeding diathesis, interstitial kidney disease\n5. Taking NSAIDs daily for other indications (e.g, chronic pain or arthritis)\n6. Known hypersensitivity to ibuprofen, diclofenac or other NSAIDs.\n7. Any known allergy or intolerance to any components or trace constituents (e.g., aloe vera, tree nuts or corn) of the investigational products\n8. Current use of prohibited medications known to impair renal function when combined with NSAIDs or cause potential additive risks of gastrointestinal toxicity and renal impairment\n9. Absence of a parent\u002Fguardian for children who are not mature minors.\n10. Caregiver and\u002For child cognitive impairment precluding the ability to complete study procedures\n11. Inability to obtain consent, and to complete follow-up surveys due to language barrier\n12. Known or suspected late pregnancy (gestational age ≥20 weeks) at the time of enrolment or breastfeeding females, due to the risk of premature closure of the ductus arteriosus associated with NSAID use\n13. Current enrollment in another pain-related clinical trial or in a study that, in the opinion of the Qualified Medical Investigator, may interfere with enrollment, involve investigational products that interact with study medications, or compromise follow-up and outcome assessment","6 Years",{"count":80,"type":20},60,[82],"PHASE3","The TOP-MAP pilot trial has multiple goals. The first goal of this pilot clinical trial is to find out if it will be possible to carry out a study at multiple pediatric emergency department sites (Peds ED) comparing Non-Steroidal Anti-Inflammatory (NSAID) gel applied to a new ankle or knee injury to NSAIDs taken by mouth in kids aged 6-18. The investigators want to determine if the gel works as well or better at reducing pain than NSAIDs given by mouth. Based on studies done on adults, the investigators know that NSAIDs that are applied directly to an injury work as well at relieving pain as NSAIDs that are taken by mouth. Another goal of this pilot trial is to determine if it is possible to recruit participants to the study, and if the participants complete the questionnaire and take the medications as prescribed on Day 1.\n\nThe participants will be in the study for 14 days. Participants will be required to take the oral NSAID medication and to apply the topical NSAID gel 3 times a day for the first 3 days after their visit to the ED. The investigators will ask the participants to rate their pain on a scale of 0 (no pain) to 10 (worst pain ever) before and after they use the medicine. On day 7, the participants will rate their pain, and their activity level. On day 14 participants will do the same.",[28,85,86,87,88],"Pediatrics","Sprain and Strain of Ankle","Sprain Knee","Strain Knee",[90,91,85,92,93],"Non Steroidal Anti-Inflammatory","Pediatric Emergency Department","Ankle or Knee Injury","Topical NSAIDs","2026-04-07",{"date":96,"type":33},"2026-04-13",{"date":98,"type":33},"2026-04-02",{"date":100,"type":20},"2028-03-31",{"name":102,"class":40},"University of Calgary",2,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":41},"100519692","phase-4-can-immediate-post-injury-fluoxetine-improve-the-recovery-trajectories-of-victims-in-bodily-trauma-100519692","NCT06046859","Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma?","Inclusion Criteria:\n\n* Admitted to UF Health for trauma resulting in:\n\n  * One or more extremity fractures requiring surgery\n  * Pelvic Fracture\n  * Chest\u002Fabdominal Injury requiring intervention in operating room\n* Polytrauma (multiple organ systems\u002Fmultiple fractures) or Beck Depression Inventory (BDI-II) ≥ 14\n\nExclusion Criteria:\n\n* Severe Traumatic Brain Injury or cognitively not able to participate in surveys. (Glasgow Coma Scale 3-8)\n* Other psychiatric conditions on current medical management (SSRI)\n* Incarceration or Pregnancy\n* Expected Injury Survival of less than 90 days\n* Medical or physical condition in opinion of investigators that would preclude safe study participation\n* Unable to provide informed consent due to language or other barriers\n* Current or previous substance abuse (excluding cannabinoids and alcohol)","85 Years",{"count":112,"type":20},200,[114],"PHASE4","With this prospective double-blinded, placebo controlled clinical trial we hypothesize that immediate (post-injury) intervention with Fluoxetine will prevent\u002Fmitigate the development of negative psychiatric symptomology such as PTSD and depression for victims of bodily trauma. We also hypothesize that immediate use of Fluoxetine will decrease subjects' pain, pain interference and opioid use without changing our standard of care post-injury pain medication regimen. Enrolled subjects will be randomized to Fluoxetine or placebo at their index hospitalization.",[28],"2026-04-06",{"date":96,"type":33},{"date":120,"type":33},"2024-03-01",{"date":122,"type":20},"2027-03-17",{"name":124,"class":40},"University of Florida",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":41},"100633017","evaluation-of-injury-risk-factors-and-effects-of-individualized-exercise-program-in-basketball-and-volleyball-athletes-100633017","NCT07521215","Evaluation of Injury Risk Factors and Effects of Individualized Exercise Program in Basketball and Volleyball Athletes","Evaluation of Injury Risk Factors With Clinical\u002FFunctional Tests and Effects of Individualized Exercise Program in University Basketball and Volleyball Athletes: A Non-Randomized Parallel-Group Study","IRISPORT","Inclusion Criteria:\n\n* Active member of Acibadem University basketball or volleyball team\n* Regular training within the past 6 months\n* Age 18 years or older\n* Willing to participate and provide written informed consent\n* Physical and cognitive capacity to complete test protocols\n\nExclusion Criteria:\n\n* Surgical intervention within the past 6 months\n* Acute musculoskeletal injury within the past 2 weeks (acute sprain\u002Fstrain\u002Fcontusion etc.) that would preclude testing\n* History of vestibular disorder, neurological disease, or systemic condition that may affect balance testing\n* Uncontrolled cardiovascular disease\u002Fhypertension or other medical condition contraindicating exercise\n* Pregnancy or within the first 6 months postpartum (female athletes)\n* Refusal to provide informed consent",{"count":134,"type":20},100,[23],"This study aims to identify injury risk factors using a clinical\u002Ffunctional test battery in university basketball and volleyball athletes, to develop individualized exercise prescriptions for athletes scoring below established cut-off values on each test, and to evaluate the effects of an 8-week intervention program on test parameters.\n\nAs a secondary aim, all participants will be monitored prospectively over a 6-month season to assess the incidence of injuries and health problems, and to evaluate the contribution of the individualized program to injury-related health outcomes.\n\nThe study consists of four phases: (1) baseline cross-sectional assessment (T0), (2) 8-week individualized exercise intervention for athletes below cut-off thresholds, (3) post-intervention reassessment (T1), and (4) 6-month prospective injury surveillance (T2).",[138,139,28],"Athletic Injuries","Sports Injury Prevention",[141,142,143,144,145,146,147,148,149,150,151,152],"injury prevention","individualized exercise","Y-Balance Test","Hop Test","Limb Symmetry Index","GIRD","CKCUEST","university athletes","basketball","volleyball","functional screening","neuromuscular training","NOT_YET_RECRUITING","2026-04-03",{"date":156,"type":33},"2026-04-09",{"date":158,"type":20},"2026-04",{"date":160,"type":20},"2026-11",{"name":162,"class":40},"Acibadem University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":41},"100499226","use-of-an-integrated-orthotic-and-rehabilitation-initiative-for-treatment-of-lower-extremity-musculoskeletal-disorders-100499226","NCT05780502","Use of an Integrated Orthotic and Rehabilitation Initiative for Treatment of Lower Extremity Musculoskeletal Disorders","Inclusion Criteria:\n\n* Minimum 18 years of age\n* Fitted with a customized exoskeletal orthosis device\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Less than 18 years of age\n* Self-reported pregnancy\n* Not fitted with a customized exoskeletal orthosis\n* Unable or unwilling to provide written informed consent",{"count":170,"type":20},370,"The Intrepid Dynamic Exoskeletal Orthosis (IDEO) is a custom, energy storage and return ankle orthosis proven to improve functional ability when coupled with a customized high-intensity rehabilitation program. The Return to Performance (RTP) clinical pathway is the civilian version of the evidence-based Return To Run (RTR) clinical pathway. Together, the CUSTOMIZED EXOSKELETAL ORTHOSIS and RTP form a novel orthotic and rehabilitation initiative. A diverse group of patients has utilized the pathway to date, including combat wounded Soldiers undergoing complex limb salvage procedures, those with muscle and tendon deficiencies, patients with postoperative nerve palsies, various lower extremity fractures and many others. With this study we are seeking to determine how participation in CUSTOMIZED EXOSKELETAL ORTHOSIS RTP clinical pathway affects patient outcomes as determined by validated functional outcome measures. Subjects will undergo testing before, during and after completion of the clinical pathway.",[28],"2026-03-11",{"date":175,"type":33},"2026-03-12",{"date":177,"type":33},"2015-05-06",{"date":179,"type":20},"2028-12",{"name":181,"class":40},"Wake Forest University Health Sciences",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":212},"100448689","post-concussion-musculoskeletal-injury-risks-100448689","NCT05122728","Post-Concussion Musculoskeletal Injury Risks","Post-Concussion Neuromuscular Function and Musculoskeletal Injury Risk","Inclusion Criteria:\n\nConcussed Cohort\n\n* 18-40 years old.\n* Self-reported asymptomatic post-concussion following enrollment into the study and monitoring of symptoms by research personnel via daily self-reported symptom questionnaires.\n* Recruited within 5 days following being diagnosed with a concussion, and at least 72 hours prior to self-reporting as asymptomatic.\n* Access to a functional email address and the internet for completion of patient reported outcomes (PROs) and musculoskeletal injury measures.\n\nNon-Concussed Cohort\n\n* 18-40 years old.\n* Active duty Service members and physically active civilians.\n* No self-report history of concussion within the previous 5 years.\n* No lingering post-concussion signs\u002Fsymptoms.\n* Same gender as the matched concussed participant.\n* Within ±5% of the matched concussed participant's height, weight, and body mass index.\n* Within ±2 years of age of the matched concussed participant.\n* Participant in the same physical activities (work, recreational sports, average type \\[no impact, low-impact, high-impact\\] and duration of physical activity)\n\nExclusion Criteria:\n\n* Post-Concussion Cohort AND Healthy Non-Concussed Cohort\n\n  * Unable to read or comprehend the English language.\n  * Admitted to the hospital following concussion.\n  * Sustained a concussion not related to physical activity participation (e.g., blast-related injury, fall from a ladder, motor vehicle accident).\n  * Loss of consciousness longer than 30 minutes.\n  * Alteration in consciousness longer than 24 hours.\n  * Post-traumatic amnesia lasting longer than 1 day.\n  * Glasgow Coma Scale below 13.\n  * Abnormal brain imaging findings.\n  * Sustained a concussion that took longer than 21 days for the individual to report as asymptomatic.\n  * A MSKI within the last 6 months that resulted in altered or missed physical activity for 3 or more consecutive days.\n  * History of MSKI surgery.\n  * Pregnant females (will be eligible for participation in the study once medically cleared to RTD\u002FA by a qualified and licensed healthcare provider following the end of the pregnancy).\n  * Participants will be excluded if they present any known contraindications for electrical stimulation. These contraindications include conditions such as: active deep vein thrombosis\u002Fthrombophlebitis, any acute injury with concurrent inflammation, hemorrhagic conditions, impaired circulation, impaired local sensations, presence of infection (osteomyelitis, tuberculosis), malignancy, recently radiated tissue, skin disease\u002Fdamage and\u002For at-risk skin.\n  * Present with any implanted pacemaker, electronic device, or plastic\u002Fcement material","40 Years",{"count":191,"type":20},148,"Musculoskeletal injuries (MSKI) and traumatic brain injury (TBI) are the signature injuries of the ongoing military conflicts. MSKI affect 800,000 Service Members annually and TBI have impacted more than 350,000 in the past 19 years and account for 22% of all combat casualties. Concussion, a mild form of TBI, increases MSKI risk in physically active individuals, including Service Members.\n\nThe overall goal of the study is to identify the neuromuscular control mechanisms that increase MSKI risk following concussion. It is hypothesized that concussed individuals will display abnormal neuromuscular function that increases MSKI risk, as compared to non-concussed controls. The study will employ a multi-center, prospective, case-matched control observational study to identify the differences in neuromuscular function following concussion that may contribute to increased MSKI risk. Once the neuromuscular control mechanisms that increase MSKI risk following concussion are identified, targeted risk mitigation strategies can be developed to reduce MSKI risk.",[28],[195,196,197,198,199,200,201],"musculoskeletal injury","biomechanics","movement assessment","neuromuscular control","traumatic brain injury","TBI","concussion","2026-01-23",{"date":204,"type":33},"2026-01-27",{"date":206,"type":33},"2022-10-20",{"date":208,"type":20},"2027-09-30",{"name":210,"class":211},"Walter Reed National Military Medical Center","FED",3,{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":21,"phases":223,"briefSummary":224,"conditions":225,"keywords":228,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":41},"100423945","the-effects-of-afo-heel-height-and-stiffness-on-gait-100423945","NCT04800484","The Effects of AFO Heel Height and Stiffness on Gait","AFOHeel","GROUP 1 Patient Inclusion criteria\n\n* Ages: 18-70\n* Daily AFO use to address unilateral, below knee functional deficits that result from limb injury or musculoskeletal disease (e.g. fracture, muscle and\u002For nerve injury, ankle arthritis)\n* Greater than 2 weeks using their current AFO\n* Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.)\n* Ability to walk at a slow to moderate pace\n* AFO fits into traditional footwear\n* Able to read and write in English and provide written informed consent\n\nGROUP 1 Patient Exclusion criteria\n\n* Pain \\> 6\u002F10 while walking during testing or an increase in pain during testing of \\> 2\u002F10.\n* Central Nervous System disorder or disease (e.g. Stroke, Cerebral Palsy, Spinal Cord Injury, or other conditions that result in lower limb spasticity).\n* Disorder or disease that affects peripheral nerve function (e.g. diabetes, Charcot Marie Tooth).\n* Limited contralateral lower limb function due to injury or neurological\u002Fmusculoskeletal disorder.\n* Use of a hinged\u002Farticulating AFO (e.g. Plantar flexion stop, Dorsiflexion assist\u002Fstop, free motion), Charcot Restraint Orthotic Walker (CROW) boot, AFOs that restrict all motion in the ankle and foot.\n* Use of an AFO that crosses the knee (Knee brace)\n* Insufficient space in shoe to accommodate the tallest heel wedge and their AFO\n* Visual or hearing impairments that limit walking ability or could limit the ability to comply with instructions given during testing\n* Pregnancy - Per participant self-report. Due the expected small number of pregnant individuals, and resulting inability to account for its effect on resulting outcomes participants will be withdrawn from the study.\n* Body Mass index \\> 40.\n\nGROUP 2 Patient Inclusion Criteria\n\n* Ages: 18-70\n* Daily AFO use to address below knee functional deficits that result from disease involving the peripheral nervous system (e.g. Charcot Marie Tooth, Multiple Sclerosis, diabetes)\n* Greater than 2 weeks using their current AFO (unilateral or bilateral)\n* Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.)\n* AFO fits into traditional footwear\n* Ability to walk at a slow to moderate pace\n* Able to read and write in English and provide written informed consent\n\nGROUP 2 Patient Exclusion Criteria\n\n* Pain \\> 6\u002F10 while walking or an increase in pain during testing of \\> 2\u002F10\n* Central Nervous System disorder or disease (e.g. Stroke, Cerebral Palsy, Spinal Cord Injury, or other conditions that result in lower limb spasticity)\n* Limited function due to limb injury (e.g. fracture, muscle and\u002For nerve injury)\n* Use of a hinged\u002Farticulating AFO (e.g. Plantar flexion stop, Dorsiflexion assist\u002Fstop, free motion), Charcot Restraint Orthotic Walker (CROW) boot, AFOs that restrict all motion in the ankle and foot.\n* Use of an AFO that crosses the knee (Knee brace)\n* Insufficient space in shoe to accommodate the tallest heel wedge and their AFO\n* Visual or hearing impairment that limit walking ability or limit the ability to comply with instructions given during testing\n* Pregnancy - Per participant self-report. Due the expected small number of pregnant individuals, and resulting inability to account for its effect on resulting outcomes participants will be withdrawn from the study\n* Body Mass index \\> 40.","70 Years",{"count":222,"type":20},40,[23],"The proposed study evaluates the effect of ankle foot orthosis (AFO) heel height and stiffness on the forces and motion of the lower limb during over-ground walking in individuals who use an AFO for daily walking. Previous studies suggest that heel height and stiffness effect limb loading, but these data and the analysis techniques applied are limited. In this study, heel cushions with different height and stiffness's (4 conditions) will be placed in participants shoes and they will walk at controlled and self-selected speeds. Participants will also walk with their AFO as configured prior to enrollment, and with no AFO if possible. The proposed study will provide evidence that can be used by clinicians and researchers to align braces that most effectively improve function during every-day walking.",[28,226,227],"Musculoskeletal Diseases","Peripheral Nervous System Diseases",[229,230,60],"Gait Analysis","Ankle Foot Orthosis","2025-12-29",{"date":233,"type":33},"2025-12-31",{"date":235,"type":33},"2019-11-07",{"date":237,"type":20},"2027-01-01",{"name":239,"class":40},"University of Iowa",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":189,"enrollmentInfo":248,"targetDuration":4,"studyType":21,"phases":250,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":41},"100551121","phase-4-adaptions-and-resiliency-to-multi-stressor-operations-100551121","NCT06455969","Adaptions and Resiliency to Multi-Stressor OpeRations","Musculoskeletal Resiliency and Adaptation to Sex Steroid Suppression and Replacement During Multi-Stressor Training","ARMOR","Inclusion Criteria:\n\n1. Age 18-40 years\n2. body mass index (BMI) 18-30 kg\u002Fm2\n3. weight stable (±10 lbs) in past 2 months\n4. takes part in moderate physical activity for at least 150 minutes\u002Fweek\n5. currently free of upper or lower body \u002Fextremity injury or impairment\n6. able to commit to study duration\n7. agrees to adhere to study requirements\n8. not taking prescription medications or be willing to refrain from medication prior to and throughout the study period, unless approved by study physician\n9. in men, total testosterone concentration within normal physiological range (300-1000 ng\u002FdL)\n10. in women, eumenorrheic (cycles of 26-35 days) and not using hormonal contraceptives for previous 3 months\n\nExclusion Criteria:\n\n1. Current smoker\n2. current clinical diagnosis of an eating disorder\n3. use of medication incompatible with measurement of reproductive and metabolic hormones or which may interfere with any of the study outcomes\n4. current oligo\u002Famenorrhea in women\n5. any metabolic or endocrine disease\n6. has been diagnosed with a medical condition, physical or psychological, that currently prevents potential subjects from exercising\n7. currently pregnant or becomes pregnant during the study\n8. history of heart condition OR high blood pressure\n9. treating physician requires subject participates in medically supervised physical activity only\n10. history of drug addiction, or regular use of recreational drugs\n11. currently undergoing treatment for or have a history of mental health conditions\n12. irregular lab results (e.g., PSA \\>3 ng\u002FmL)\n13. Current diagnoses of disorders known to affect bone metabolism including hyperthyroidism, hyperparathyroidism, osteomalacia, Cushing's, diabetes mellitus or renal insufficiency\n14. Current use of medications known to affect bone metabolism including estrogens, androgens, anti-estrogens, bisphosphonates (oral bisphosphonates within one year of the baseline visit or IV bisphosphonates within three years of the baseline visit), calcitonin, fluoride, oral or inhaled glucocorticoids, suppressive doses of thyroxine, lithium, pharmacological doses of vitamin D (greater than 2000 IU\u002Fday), anti-convulsants, depot medroxyprogesterone within 6 months.\n15. History of deep vein thrombosis, pulmonary embolism, or clotting disorders.\n16. History of stroke or myocardial infarction\n17. Serum 25-hydroxyvitamin D \\\u003C 20 ng\u002FmL\n18. Thyroid dysfunction\n19. Serum creatinine \\> 2 mg\u002FdL\n20. Personal history or history of a first-degree relative with breast cancer\n21. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\> 2x the upper limit of normal\n22. Serum bilirubin \\> 2 mg\u002FdL\n23. Serum alkaline phosphatase \\> 150 U\u002FL\n24. Plasma hemoglobin \\\u003C 10 gm\u002FdL\n25. Hematocrit \\> 50\n26. Fracture within the last 6 months.\n27. Serum testosterone level \\\u003C 270 or \\> 1070 ng\u002FdL\n28. Systolic blood pressure \\> 160 or diastolic blood pressure \\> 95\n29. Active substance abuse\n30. Triglycerides \\> 150 fasting\n31. History of hereditary angioedema\n32. History of chest pain at rest, during daily activities of living, or when performing physical activity\n33. Musculoskeletal injury removing subject from physical activity for more than a month within the past 2 years\n34. Recreational drug use more than 2 times per month in each of the previous 6 months\n35. Self-reported vision is worse than 20\u002F20.\n36. Personal history or history of a first-degree relative with breast cancer\n37. Experienced a fracture within the last 6 months\n38. participated and taken investigational drug in any other clinical trial (including bioequivalence study) within six months prior to study drug administration\n39. Diagnosed with eating disorder\n40. Have food allergies, intolerance, restriction, or special diet needs\n41. History of endometriosis\n42. Current diagnosis of reproductive health issues, such as ovarian cysts, PCOS, pelvic lesions, undiagnosed ovarian enlargement\n43. Have undiagnosed abnormal vaginal bleeding\n44. Currently breastfeeding or within 2 months after stopping breastfeeding\n45. Have dietary restrictions",{"count":249,"type":20},120,[114],"Non-combat-related muscle, tendon and bone injuries are the most common injuries suffered by military personnel, particularly in new recruits. These injuries impact military readiness and are responsible for roughly 60% of limited duty days, 65% of soldiers who are unable to deploy, and nearly $500 million in medical cost to the government annually in the Army alone. Drug interventions must be studied and developed to prevent these negative outcomes and prepare military personnel for the demands of military service. At the current time, military leadership has identified critical gaps in understanding how to minimize these injuries and train soldiers with drug intervention serving among those gaps.\n\nThe goal of this study is to determine how a hormonal intervention can change muscle, tendon, and bone function as well as physical and psychological performance in response to mental and physical stress. To do so, we will examine sex hormone (testosterone, estrogen) levels, muscle, tendon, and bone images, blood samples, and physical and mental performance. We will look at things like changes in hormone levels, chemicals released from active skeletal muscles, and your body composition. The results from this study will be used to improve physical readiness training in the military with the goal of reducing injuries.",[28,253],"Hypogonadism",[255,256,257,258,259],"Military","Multi-stressor Training","Tendon","Muscle","Bone","2025-08-18",{"date":262,"type":33},"2025-08-24",{"date":264,"type":33},"2024-07-15",{"date":266,"type":20},"2026-08-01",{"name":268,"class":40},"Bradley Nindl",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":48,"sex":276,"minAge":17,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":21,"phases":278,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":293,"locationsCount":41},"100557457","running-online-injury-prevention-feasibility-study-100557457","NCT06538363","Running Online Injury Prevention Feasibility Study","ROIPF","Inclusion Criteria:\n\n* Cis-gender female (someone who was born female and currently identifies as a woman) runners\n* Over the age of 18\n* Have not been injured in the last 3 months (\\*\\*For the purpose of this study, an injury is defined as \"musculoskeletal (originating from the bones, muscles, joints) that has restricted the ability to run in any way (distance, speed, duration) for at least 7 days or for 3 consecutive training sessions\"\\*\\*)\n* Have run on average 3 times\u002Fweek for the last 6 months\n* Own a GPS-enabled smart watch with an optical wrist heart rate sensor\n* Fit shoe size between 6.5 and 8.5 US women's sizing\n* Able to attend one of the in-person orientation sessions\n* Able to understand written and spoken English\n\nExclusion Criteria:\n\n* Any current pain with running","FEMALE",{"count":80,"type":20},[23],"The main purpose of this study is to test the feasibility of a larger scale interventional study. The investigators want to understand whether data can be reliably collected data various different streams while participants follow a standard 12-week half-marathon training program, and whether participants follow training recommendations.",[28],[282,283,60,284,285,286],"Running","Wearable sensors","Training","Education","Female athlete","2024-08-01",{"date":289,"type":33},"2024-08-05",{"date":287,"type":20},{"date":292,"type":20},"2025-01-01",{"name":294,"class":40},"Simon Fraser University",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":302,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":41},"100523802","exercise-engagement-in-people-over-60-at-risk-of-falls-100523802","NCT06100445","Exercise Engagement in People Over 60 at Risk of Falls","Barriers and Facilitators to Exercise Engagement in People Over 60 at Risk of Falls: an Exploratory Study","Inclusion Criteria:\n\n* Aged 60 years or over\n* At risk of falls or had a fall due to a musculoskeletal cause (pain, muscle weakness, balance issue)\n* Has capacity to consent, as deemed by the direct care team and researcher\n* Can communicate in English OR the use of a translation service - Able to independently participate in an interview either face-to-face or via remote means OR can use a translation service\n\nExclusion Criteria:\n\n\\- Aged under 60\n\n* Have a medical cause of falls OR currently under investigation for a medical cause of falls (eg\u002F dizziness, cardiac, visual impairment reported as being the cause of the fall as opposed to weakness or pain in lower limbs\u002Fbalance issues or unsteady on feet)\n* Moderate to severe cognitive impairment impairing capacity to consent","60 Years","95 Years",{"count":305,"type":20},10,"It is a qualitative study, using semi structured interviews to explore patient's experiences of falls and their perceptions on facilitators and barriers to exercise.\n\nAim: To explore reasons for and against engaging with exercises at home in participants over the age of 60 at risk of falls.\n\nTo explore:\n\n1. Patients' preferences to exercise format and type eg\u002F leaflet, online, access, such as the Chartered Society of Physiotherapy (CSP) chair exercises leaflet or individual personalized rehabilitation programme handouts\n2. The ability to discuss falls risk with health professionals.\n3. If health inequalities exist with people at risk of falls and exercising.\n4. Sustainability of exercise, in order to reduce the risk of falls in this population.\n5. The need to develop MSK internal and external facing falls management pathways.\n\nSuitability: Patients over the age of 60, who have been identified at risk of falls, having been referred to MSK Physiotherapy in Rossendale.\n\n'Risk of falls' is defined as: patient self-reports they are unsteady, had one or more fall in the last 6 months, or clinician identified a slow\u002Funsteady gait pattern on examination.\n\nSemi structured interviews on up to ten participants. It is anticipated that this sample size will give adequate data saturation. Approximately 12 months from participant recruitment to analysis of findings.",[28,308,309,310],"Frailty","Physical Inactivity","Health Behavior","2024-06-20",{"date":313,"type":33},"2024-06-21",{"date":315,"type":33},"2024-01-26",{"date":317,"type":20},"2024-12-31",{"name":319,"class":40},"East Lancashire Hospitals NHS Trust",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":21,"phases":328,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":41},"100521837","phase-1-a-study-of-human-allogeneic-bone-marrow-derived-mesenchymal-stromal-cell-product-stromaforte-in-patients-with-musculoskeletal-injuries-andor-degeneration-100521837","NCT06074783","A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and\u002For Degeneration","A Patient Sponsored Ongoing Open-label Single-arm, Safety and Efficacy, Phase I\u002FIIb Study of Cellcolabs´ Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and\u002For Degeneration","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent and comply with all procedures required by the protocol.\n2. Aged ≥ 18 years at the time of signing the informed consent form and has any diagnosed musculoskeletal injury and\u002For degenerative conditions.\n\nExclusion Criteria:\n\n1. Unwilling or unable to perform any of the assessments required by the protocol.\n2. Have an injury that is expected to selfheal within 14 days without remaining sequel.\n3. Have an injury for which there is solid scientific evidence that the study compound will have no effect.\n4. Have traumatic head injury or skull, teeth or jaw injury as diagnosis for inclusion in trial.\n5. Have an injury that require an orthopaedic surgery that has not been addressed by local\u002Fhome surgeon.\n6. Have end stage liver or renal disease.\n7. Have a clinical history of malignancy within 2.5 years (i.e., patients with prior malignancy must be cancer free for 2.5 years) except curatively treated basal cell carcinoma, melanoma in situ, or cervical carcinoma.\n8. Have any condition that limits lifespan to \\\u003C 1 year according to the Principal Investigator's discretion.\n9. Hepatitis B virus positive\n10. Viraemic Hepatitis C virus, HIV-1\u002F2 or syphilis positive\n11. Have unstable angina pectoris, uncontrolled or severe peripheral artery disease within the previous 2 months.\n12. Have congestive heart failure defined by New York Heart Association (NYHA) Class IV, or an ejection fraction of \\\u003C25%.\n13. Uncontrolled hypertension (resting systolic blood pressure \\>220 mm Hg or diastolic blood pressure of \\> 150 mm Hg at screening) .\n14. Have coronary artery bypass surgery, angioplasty, peripheral vascular disease revascularization, or a myocardial infarction within the previous month.\n15. Have acute exacerbation of chronic obstructive lung disease stage III or IV (Gold classification), Have cognitive or language barriers that prohibit obtaining informed consent or any study elements.\n16. Severe acute infection at time of screening and treatment with study drug\n17. Pregnant or Breastfeeding\n18. Currently participating (or participated within the previous 30 days of consent) in an investigational therapeutic or device trial.\n19. Have a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the patient's participation for the full duration of the study.",{"count":19,"type":20},[329,330],"PHASE1","PHASE2","The goal of this ongoing open-label, single-arm, phase I\u002FIIa study in patients is designed to assess the safety of human allogeneic BM-derived MSCs product StromaForte for musculoskeletal injury or\u002Fand degeneration. Any male or female with any musculoskeletal injury and\u002For degeneration above 18 years will be enrolledThe main questions it aims to answer are:\n\nTo assess the safety after 28±10, 84±10, 168±10 and 349±10 days of injection by reporting the number of adverse events or severe adverse event assessed by Common Terminology Criteria\n\nChange from baseline in subjective pain assessment in each injured and\u002For degenerated area (if multiple injury is reported, each area to be followed up separately)\n\nEligible patients will receive 50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given locally under ultrasound guidance along with or without 100 x 106 allogeneic BM-derived MSCs formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min. Systemic treatment alone is used when local injection at site of injury is not feasible. Additional dose can be administered.",[28],"2024-04-17",{"date":335,"type":33},"2024-04-19",{"date":337,"type":33},"2023-10-20",{"date":339,"type":20},"2028-10-19",{"name":341,"class":342},"Cellcolabs Clinical LTD.","INDUSTRY",{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":16,"minAge":349,"maxAge":17,"enrollmentInfo":350,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":41},"100447768","quality-of-life-and-life-satisfaction-in-pediatric-and-adolescent-gymnasts-through-injury-100447768","NCT05110729","Quality of Life and Life Satisfaction in Pediatric and Adolescent Gymnasts Through Injury","Inclusion Criteria:\n\n* Male and female gymnasts ages 8-18 years old\n* Participating in Excel or Developmental gymnastics programs who present to Children's Hospital Colorado sports medicine or orthopedic clinics with a musculoskeletal injury.\n\nExclusion Criteria:\n\n* Gymnasts only participating in Colorado Association for Recreational Athletics (CARA) gymnastics, retired gymnasts, and adult or collegiate gymnasts.\n* Vulnerable populations (prisoners, pregnant women, individuals with decreased decision making capacity(","8 Years",{"count":351,"type":20},1218,"This study aims to assess the quality and life and life satisfaction of pediatric and adolescent gymnasts throughout their musculoskeletal injury recovery.",[28,354],"Quality of Life",[356,357],"Gymnastics","Quality of Life and Life Satisfaction","2024-04-01",{"date":360,"type":33},"2024-04-02",{"date":362,"type":33},"2021-11-12",{"date":160,"type":20},{"name":365,"class":40},"University of Colorado, Denver"]